What the Tempus and Personalis Filing Said About Antitrust Clearance
Personalis told the Securities and Exchange Commission that the waiting period for the Tempus mergers under the Hart-Scott-Rodino Act expired at 11:59 p.m. Eastern time on October 2, 2026. The filing notes Tempus refiled its antitrust notice on September 2, 2026, which restarted a fresh 30 day waiting period. The filing states the closing still depends on Personalis stockholder approval at a stockholders meeting plus the other closing conditions in the merger agreement. Tempus announced the deal on July 20, 2026 at 16.25 dollars per Personalis share, which it put at 1.5 billion dollars of enterprise value after counting the Tempus stake it already held, structured as an all-stock deal with the option to pay cash for up to half the shares.
Why the Tempus Personalis Deal Matters to Oncology Buyers and Investors
Antitrust clearance removes the hurdle a buyer cannot control, and it leaves a shareholder vote that usually follows the board. For a health system already buying Tempus genomic reports, the useful question is what happens to Personalis NeXT Personal pricing, contracts and lab turnaround once one company owns both. Clearance is not closing, so nothing about today's ordering changes yet, and the deal could still be voted down or fail another condition.
Where the Tempus Update Comes From
Personalis SEC Form 8-K is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.
Personalis SEC Form 8-K original source.
How We Would Research the Tempus Personalis Merger
The source gives us the starting point. This is how we would build the next layer of research around it.
- We would start with the proxy statement for the stockholders meeting, because it names the vote date and the board's own reasons.
- Then we would read the merger agreement's closing conditions to see which ones are still open besides the vote.
- We would ask both companies in writing whether existing minimal residual disease test contracts and prices carry over unchanged after closing.